Background The combination of ivosidenib—an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1)—and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

Background Mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) occur in 6 to
10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted …

PURPOSE Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1)
enzyme, approved for treatment of IDH1-mutant (m IDH1) acute myeloid leukemia (AML) …

Background Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2)
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …

Abstract Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the
oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 …

Summary Background Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule
inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 …

Abstract Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the
mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their …

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy;
approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes …

Abstract IDH2 (isocitrate dehydrogenase 2) mutations occur in approximately 15% of
patients with acute myeloid leukemia (AML). The IDH2 inhibitor enasidenib was recently …

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in∼ 12% of patients with
acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2 …